Atea Pharmaceuticals (AVIR) Projected to Post Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to announce its earnings results after the market closes on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Atea Pharmaceuticals Price Performance

Atea Pharmaceuticals stock opened at $2.90 on Wednesday. The firm has a 50 day simple moving average of $3.17 and a 200-day simple moving average of $3.36. Atea Pharmaceuticals has a 1-year low of $2.75 and a 1-year high of $4.18. The stock has a market cap of $244.94 million, a price-to-earnings ratio of -1.40 and a beta of 0.19.

Insider Activity

In other news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total value of $1,024,877.10. Following the completion of the sale, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.